Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- WORLD BUSINESS NEWS IN BRIEF
March 12, 2001
- Nomura BioConference Focuses on Latest Biotechnology -1-
March 12, 2001
- BUSINESS NEWS IN BRIEF -1-
March 12, 2001
- Nomura BioConference Focuses on Latest Biotechnology -2-
March 12, 2001
- Elsevier Science Acquires MIX
March 12, 2001
- Hitachi Spins Off Instruments, Semiconductor Manufacturing Equipment Businesses
March 12, 2001
- Maruishi: Sevofrane Pushes Sales to \32 Bil., Up 6.4%
March 12, 2001
- Mitsubishi Ties Up with TeraRecon in 3D Graphics Business
March 12, 2001
- Approval of 8 New Drugs Including Radicut, Fiblast Spray Granted
March 12, 2001
- DIAGNOSTIC NEWS IN BRIEF
March 12, 2001
- More Strict with Hospitals in Illegal Cases: New Medical Service Law
March 12, 2001
- OTC NEWS IN BRIEF
March 12, 2001
- Nicorette Reexamined, 2 New Orphan Drugs Designated
March 12, 2001
- Sankyo Aims at \1 Trillion Sales in FY2010: President Takato
March 12, 2001
- Q&A Booklet on New PMS for 6 Months after Launching Issued
March 12, 2001
- MTP Ties Up with Sumitomo, MedGene Regarding HGF
March 12, 2001
- REGULATORY NEWS IN BRIEF
March 12, 2001
- Hokuriku: Hokunalin Tape, Ganaton Boost Sales, Operating Profits
March 12, 2001
- Taisho Signs Anti-Asthma Drug License Agreement with EpiGenesis
March 12, 2001
- JMARI to Conduct Survey to Propose New Medical Fee Payment Method
March 12, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…